Inozyme Issuance Purchase of Equity Shares from 2010 to 2024
| INZY Stock | USD 4.39 0.12 2.66% |
Check Inozyme PharmaInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 1.4 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.11 or PTB Ratio of 1.65. Inozyme financial statements analysis is a perfect complement when working with Inozyme PharmaInc Valuation or Volatility modules.
Inozyme | Issuance Purchase of Equity Shares |
About Inozyme PharmaInc Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Inozyme PharmaInc income statement, its balance sheet, and the statement of cash flows. Inozyme PharmaInc investors use historical funamental indicators, such as Inozyme PharmaInc's Issuance Purchase of Equity Shares, to determine how well the company is positioned to perform in the future. Although Inozyme PharmaInc investors may use each financial statement separately, they are all related. The changes in Inozyme PharmaInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inozyme PharmaInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inozyme PharmaInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inozyme PharmaInc. Please read more on our technical analysis and fundamental analysis pages.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Inozyme Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inozyme PharmaInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inozyme PharmaInc's short interest history, or implied volatility extrapolated from Inozyme PharmaInc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Inozyme PharmaInc Correlation against competitors. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.Note that the Inozyme PharmaInc information on this page should be used as a complementary analysis to other Inozyme PharmaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Inozyme Stock analysis
When running Inozyme PharmaInc's price analysis, check to measure Inozyme PharmaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme PharmaInc is operating at the current time. Most of Inozyme PharmaInc's value examination focuses on studying past and present price action to predict the probability of Inozyme PharmaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme PharmaInc's price. Additionally, you may evaluate how the addition of Inozyme PharmaInc to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Inozyme PharmaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme PharmaInc. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme PharmaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Return On Assets (0.28) | Return On Equity (0.55) |
The market value of Inozyme PharmaInc is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme PharmaInc's value that differs from its market value or its book value, called intrinsic value, which is Inozyme PharmaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme PharmaInc's market value can be influenced by many factors that don't directly affect Inozyme PharmaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme PharmaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme PharmaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme PharmaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.